title: [Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer].
abstract: OBJECTIVE
  As a project of the Kanagawa Colorectal Cancer Study Group, we performed this study to analyze the efficacy and the safety of modified FOLFIRI (irinotecan: 150 mg/m2) therapy for Japanese patients with metastatic colorectal cancer.
  
  
  METHODS
  We treated PS 0-1 Japanese patients with measurable or assessable colorectal cancer who either had not received preliminary treatment, or were postoperative with metastasis and had undergone radiation therapy or adjuvant chemotherapy before more than four weeks, and further had provided written acceptance of our proposed procedures. Twenty patients received modified FOLFIRI therapy as a 2-hour infusion of CPT-11 150 mg/m/2 and l-LV 200 mg/m2 followed by a bolus 5-FU 400 mg/m/2 and 46-hour infusion 5-FU 2, 400 mg/m2. Tumor response was assessed by RECIST and toxicity by NCI-CTC.
  
  
  RESULTS
  Thirty males and seven females underwent an average 10 courses of treatment. This therapy achieved a 50% response rate, 80%disease-control rate, and 316+/-40 days PHS. Regarding hematological toxicity, 11 patients (55%) experienced leukemia, which developed to grade 3/4 in 5 (25%) of them. Twelve patients (65%) experienced neutropenia, which developed to grade 3/4 in 10 (50%) of them. Digestive toxicity was observed in 16 patients (80%), which developed to grade 3/4 in only one patient (5%) with gastric ulcer. Six patients (30%) experienced alopecia, which was grade 1/2 only.
  
  
  CONCLUSIONS
  This clinical study was safely carried out. The efficacy was as good as in previous reports using a regular dose of CPT-11.
authors.affiliation: Department of Surgery, Yokohama City University, Yokohama City University Hospital.
authors.forename: Norio
authors.initials: N
authors.lastname: Yukawa
authors.forename: Yuji
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Makoto
authors.initials: M
authors.lastname: Akaike
authors.forename: Manabu
authors.initials: M
authors.lastname: Shiozawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Takahashi
authors.forename: Ryuji
authors.initials: R
authors.lastname: Shiraishi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsukawa
authors.forename: Hiroharu
authors.initials: H
authors.lastname: Suzuki
authors.forename: Isao
authors.initials: I
authors.lastname: Tamura
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Ozawa
authors.forename: Naoto
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Rino
authors.forename: Munetaka
authors.initials: M
authors.lastname: Masuda
authors.forename: Toshio
authors.initials: T
authors.lastname: Imada
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D044466:Asian People; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015996:Survival Rate
chemical_list: D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin